Trifecta研究:比较供者来源游离DNA血浆水平与肾移植活检分子表型
前瞻性多中心Trifecta研究收集289例肾移植受者300次活检组织,比较活检前血浆dd-cfDNA(%)与活检组织全基因组基因表达。结果显示dd-cfDNA(%)与活动性分子排斥反应强相关,对活动性抗体介导排斥反应相关性最强,且分子排斥变量比组织学变量更能预测dd-cfDNA(%)。
要点
- dd-cfDNA(%)与活动性分子排斥反应强相关,与活动性抗体介导排斥反应相关性最强。
- 与dd-cfDNA(%)相关性最强的20个探针组均与抗体介导排斥反应及各类排斥反应相关。
- 分子排斥变量比组织学变量更能预测dd-cfDNA(%),提示其可能减少不必要的活检。
核心结论
- 指征活检时dd-cfDNA(%)与活动性分子排斥反应强相关,有潜力减少不必要的活检。
研究设计与样本
- 前瞻性多中心Trifecta研究,收集289例肾移植受者的300次活检组织,比较活检组织全基因组基因表达与活检前血浆dd-cfDNA(%)。
- 排斥反应采用基于微阵列的分子显微镜诊断系统评估,自动分配排斥原型并出具分子报告,组织学评估遵循Banff指南。
主要发现
- 活检距移植中位时间为455天(5天至32年),病例构成:180例(60%)无排斥反应,89例(30%)抗体介导排斥反应,31例(10%)T细胞介导排斥反应及混合型。
- 全基因组mRNA检测中,与dd-cfDNA(%)相关性最强的20个探针组均先前被注释与抗体介导排斥反应及各类排斥反应相关,为自然杀伤细胞表达(如GNLY、CCL4、TRDC、S1PR5)或IFN-γ诱导(如PLA1A、IDO1、CXCL11、WARS)。
- dd-cfDNA(%)与抗体介导排斥反应及各类排斥反应相关性很强,与活动性T细胞介导排斥反应相关性较强,与无活动性T细胞介导排斥反应、肾损伤及萎缩纤维化相关性弱。
- 活动性抗体介导排斥反应、混合型及活动性T细胞介导排斥反应的dd-cfDNA(%)最高,而晚期抗体介导排斥反应和活动度较低的T细胞介导排斥反应的dd-cfDNA(%)较低。
- 多变量随机森林和逻辑回归分析显示,分子排斥变量比组织学变量更能预测dd-cfDNA(%)。
临床怎么用
- 作者认为指征活检时dd-cfDNA(%)与活动性分子排斥反应强相关,有潜力减少不必要的活检。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The relationship between the donor-derived cell-free DNA fraction (dd-cfDNA[%]) in plasma in kidney transplant recipients at time of indication biopsy and gene expression in the biopsied allograft has not been defined. METHODS: In the prospective, multicenter Trifecta study, we collected tissue from 300 biopsies from 289 kidney transplant recipients to compare genome-wide gene expression in biopsies with dd-cfDNA(%) in corresponding plasma samples drawn just before biopsy. Rejection was assessed with the microarray-based Molecular Microscope Diagnostic System using automatically assigned rejection archetypes and molecular report sign-outs, and histology assessments that followed Banff guidelines. RESULTS: The median time of biopsy post-transplantation was 455 days (5 days to 32 years), with a case mix similar to that of previous studies: 180 (60%) no rejection, 89 (30%) antibody-mediated rejection (ABMR), and 31 (10%) T cell-mediated rejection (TCMR) and mixed. In genome-wide mRNA measurements, all 20 top probe sets correlating with dd-cfDNA(%) were previously annotated for association with ABMR and all types of rejection, either natural killer (NK) cell-expressed (e.g., GNLY, CCL4, TRDC, and S1PR5) or IFN-γ-inducible (e.g., PLA1A, IDO1, CXCL11, and WARS). Among gene set and classifier scores, dd-cfDNA(%) correlated very strongly with ABMR and all types of rejection, reasonably strongly with active TCMR, and weakly with inactive TCMR, kidney injury, and atrophy fibrosis. Active ABMR, mixed, and active TCMR had the highest dd-cfDNA(%), whereas dd-cfDNA(%) was lower in late-stage ABMR and less-active TCMR. By multivariate random forests and logistic regression, molecular rejection variables predicted dd-cfDNA(%) better than histologic variables. CONCLUSIONS: The dd-cfDNA(%) at time of indication biopsy strongly correlates with active molecular rejection and has the potential to reduce unnecessary biopsies. CLINICAL TRIAL REGISTRATION NUMBER: NCT04239703.
引用
- Halloran PF, Reeve J, Madill-Thomsen KS, et al. The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies. J Am Soc Nephrol. 2022. PMID: 35058354. doi:10.1681/ASN.2021091191
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。